Amylin Pharmaceuticals Inc - Current report filing (8-K)
May 22 2008 - 4:11PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13
or 15(d) of
the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported):
May 20, 2008
AMYLIN PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or Other
Jurisdiction of
Incorporation)
|
|
0-19700
(Commission File Number)
|
|
33-0266089
(I.R.S. Employer Identification No.)
|
9360 Towne Centre Drive
San Diego, California 92121
(Address of principal executive offices and zip code)
Registrants telephone number, including area
code:
(858)
552-2200
Check the appropriate box below if the Form 8-K is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (
see
General
Instruction A.2. below):
o
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CRF 240.13e-4(c))
Item
5.02. Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
On May 20, 2008, Alain D. Baron, M.D.
resigned his position as Amylins Senior Vice President, Research, effective June 1,
2008. Dr. Baron served in various
officer-level positions with Amylin since December 1999 and was a named
executive officer in Amylins 2008 proxy statement. We anticipate entering into a consulting
arrangement with Dr. Baron pursuant to which he will provide transitional
services to the company.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
AMYLIN
PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
Dated:
|
May 22,
2008
|
By:
|
/s/
Lloyd A. Rowland
|
|
|
|
Lloyd A. Rowland
|
|
|
|
Vice
President, Governance and Compliance, and
Corporate Secretary
|
3
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024